Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program.
Fanny Le DuMatthieu CartonThomas BachelotMahasti SaghatchianBarbara PistilliEtienne BrainDelphine LoiratLaurence VanlemmensThomas VermeulinGeorge EmileAnthony GonçalvesMony UngMarie RobertAnne JaffreIsabelle DesmoulinsChristelle JouannaudLionel UwerJean Marc FerreroMarie-Ange Mouret-ReynierWilliam JacotMichaël ChevrotSuzette DelalogeVéronique DiérasPublished in: The oncologist (2023)
Among patients with relapsed HER2+ MBC, the receipt of adjuvant trastuzumab did not independently predict for worse outcomes when adjusted to other prognostic factors.